Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome‐associated prostate alterations: An experimental study in the rabbit
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Phosphodiesterase type 5 (PDE5) inhibitors improve benign prostatic hyperplasia (BPH)‐related lower urinary tract symptoms (LUTS), often associated with metabolic syndrome (MetS). This study investigated the effects of PDE5 inhibition in the prostate of rabbits fed a high fat diet (HFD) for 12 weeks. HFD‐rabbits develop the most important features of human MetS (glucose intolerance, dyslipidemia, increased abdominal adiposity, and hypertension), along with hypogonadism and LUT abnormalities (prostate and bladder inflammation/tissue remodeling). METHODS: Gene expression was evaluated by quantitative RT‐PCR. Prostate morphological changes and oxygenation were evaluated by immunohistochemistry. RESULTS: HFD prostates showed increased PDE5 expression, suggesting a peculiar sensitivity of prostate to the action of PDE5 inhibitors during MetS. Accordingly, prostate PDE5 mRNA was negatively associated to plasma testosterone/estradiol ratio, whose reduction characterizes MetS, and positively with the expression in prostate of several genes exploring pathogenetic processes for BPH/LUTS, such as inflammation, leukocyte infiltration, and fibrosis/myofibroblast activation. Most of these genes was up‐regulated by HFD, and significantly reduced by PDE5 inhibition, through either chronic (12 weeks) or, at a lower extent, acute (1‐week) tadalafil dosing. Tadalafil was also able to reduce blood pressure and visceral fat in HFD rabbits, without changing any other MetS parameter. Interestingly, 1‐week tadalafil administration to HFD rabbits, significantly blunted prostate inflammation (increased CD45 immunopositivity), fibrosis (reduced muscle/fiber ratio) and hypo‐oxygenation, thus suggesting a potential curative effect of PDE5 inhibition on MetS‐related prostate alterations. CONCLUSIONS: Our data provide the experimental evidences to support the multiple potentiality of PDE5 inhibitors as a useful therapeutic tool in LUTS. Prostate 73: 428–441, 2013. © 2012 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354 · cited 1×
“Features of this syndrome include: insulin resistance (hyperinsulinemia, impaired glucose tolerance, and type 2 diabetes mellitus), dyslipidemia (hypertriglyceridemia and low serum high-density lipoprotein cholesterol), visceral fat accumulation, and hypertension [1].”
BackgroundDifferentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452 · cited 1×
“On the basis of the cytokine produced and on the functions exhibited, CD4þ T helper cells can be distinguished into three distinct effector subpopulations: Th1, Th2, and Th17, based on the stable expression of specific transcription factors Tbet, RORgt, and GATA3, respectively [32].”
BackgroundTestosterone and Metabolic Syndrome: A Meta-Analysis Study
Corona, G., Monami, M., Rastrelli, G., Aversa, A., Tishova, Y., Saad, F., Lenzi, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01991.x · Cited by 400 · cited 1×
“As described in humans [33], MetS-like syndrome in rabbit was associated with an imbalance of sex steroids plasma levels.”
BackgroundSelf-citationCorona, G., Mannucci, E., Forti, G., & Maggi, M. (2009) · International Journal of Andrology · doi:10.1111/j.1365-2605.2008.00951.x · Cited by 223
Self-citationFilippi, S., Vignozzi, L., Morelli, A., Chavalmane, A. K., Sarchielli, E., Fibbi, B., Saad, F., Sandner, P., Ruggiano, P., Vannelli, G. B., et al. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01467.x · Cited by 166
Self-citationHanda, P., Tateya, S., Rizzo, N. O., Cheng, A. M., Morgan-Stevenson, V., Han, C.-Y., Clowes, A. W., Daum, G., O'Brien, K. D., Schwartz, M. W., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.236554 · Cited by 86 · cited 1×
“Moreover, it has been reported that PDE5 inhibition attenuated HFD-induced proinflammatory cytokine expression and the recruitment of macrophages into adipose tissue [36].”
Background
Cited by
Isidori, A. M., Buvat, J., Corona, G., Goldstein, I., Jannini, E. A., Lenzi, A., Porst, H., Salonia, A., Traish, A. M., & Maggi, M. (2014) · European Urology · doi:10.1016/j.eururo.2013.08.048 · Cited by 314
Self-citationBenign prostatic hyperplasia: a new metabolic disease?
Vignozzi, L., Rastrelli, G., Corona, G., Gacci, M., Forti, G., & Maggi, M. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0051-3 · Cited by 174
“drome and tissue remodeling [48, 73], as well as bladder dysfunction [49], were demonstrated in MetS rabbits.”
BackgroundSelf-citationObesity and late-onset hypogonadism
Corona, G., Vignozzi, L., Sforza, A., Mannucci, E., & Maggi, M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.031 · Cited by 154
Self-citationMorelli, A., Sarchielli, E., Comeglio, P., Filippi, S., Vignozzi, L., Marini, M., Rastrelli, G., Maneschi, E., Cellai, I., Persani, L., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.017 · Cited by 107
Self-citationToledo-Ibelles, P., Gutiérrez-Vidal, R., Calixto-Tlacomulco, S., Delgado-Coello, B., & Mas-Oliva, J. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2021.04.005 · Cited by 64
Metadata
- Authors
- Morelli, A., Comeglio, P., Filippi, S., Sarchielli, E., Vignozzi, L., Maneschi, E., Cellai, I., Gacci, M., Lenzi, A., Vannelli, G. B., & Maggi, M.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2012-09-19
- Volume
- 73
- Issue
- 4
- Pages
- 428-441
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2089521599
- Cited by
- 87
- References
- 6
- FWCI
- 11.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.